A Phase 2 Study of TL118 for the Treatment of Patients With Solid Tumors Harboring NTRK Gene Fusions
Latest Information Update: 07 Aug 2025
At a glance
- Drugs TL 118 (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
Most Recent Events
- 22 Jul 2025 Planned End Date changed from 30 Apr 2026 to 30 Apr 2027.
- 22 Jul 2025 Planned primary completion date changed from 31 Aug 2025 to 31 Aug 2026.
- 16 Aug 2024 Planned End Date changed from 1 Dec 2025 to 30 Apr 2026.